Search Results
Results found for "Tim Dyer"
- Addex Therapeutics CEO Tim Dyer: There is a $4-bil market opportunity in dyskinesia
January 2022 "Watch our CEO Tim Dyer on AlphaStreet. In his interview, Mr. Dyer provides an overview of our #allostericmodulator pipeline and the potential $4 billion market for
- Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with ...
2022 Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with Tim Dyer Addex Therapeutics "Tim Dyer is the Co-Founder and CEO of Addex Therapeutics, which is focusing
- Addex Therapeutics To Release Full-Year 2021 Financial Results And Host Conference Call On March 10
Tim Dyer, CEO, Roger Mills, CMO and Robert Lütjens, Head of Discovery Biology, will provide a business
- Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
our strategic priorities, including pursuing additional collaborations across our portfolio,” said Tim Dyer, CEO of Addex.
- Dr. Tim De Groof - Dr. GPCR Podcast
Tim De Groof! It’s not often when you get the best of both worlds - nano-bodies and #GPCRs.
- 📰 GPCR Weekly News, November 6 to November 12, 2023
: the present as prologue Industry News Exscientia Business Update for Third Quarter 2023 Addex CEO Tim Dyer to Discuss Allosteric Modulators in Neurological Disorders at Jefferies Healthcare Conference in
- Dr. Ben Myers - Dr. GPCR Podcast
Ben Myers!
- 📰 GPCR Weekly News, December 11 to 17, 2023
Receptor (GIPR) Revealed by Trapped-Ion-Mobility Spectrometry Coupled to Time-of-Flight Mass Spectrometry (TIMS-TOF
- Glyco-sulfo hotspots in the chemokine receptor system
which have an established role in chemokine gradients and oligomerization (Deshauer C et al. 2015; Dyer
- 📰 GPCR Weekly News, May 22 to 28, 2023
Complexes Industry News Mavorixafor reduces infection rates among patients with WHIM syndrome Bristol Myers
- 📰 GPCR Weekly Buzz: Exciting Schedule Shifts for Principles of Pharmacology I & II | August 12-18, 2024
This week's highlight includes congrats to: Madison Walker , Benjamin Myers , et al., for their research Structural and Molecular Insights into GPCR Function Monitoring GPCR conformation with GFP-inspired dyes
- 📰 GPCR Weekly News, February 13 to 19, 2023
Quantitative analysis of sterol-modulated monomer-dimer equilibrium of the β1-adrenergic receptor by DEER
- 📰 GPCR Weekly News, February 6 to 12, 2023
Quantitative analysis of sterol-modulated monomer-dimer equilibrium of the β1-adrenergic receptor by DEER
- 📰 GPCR Weekly News, September 11 to 17, 2023
Ben Myers and Dr. Niña Caculitan.
- 📰 GPCR Weekly News, March 11 to 17, 2024
controls midgut development in Drosophila Karuna Therapeutics announces that is now part of Bristol Myers
- 📰 GPCR Weekly News, January 30 to February 5, 2023
Industry News Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta
- Decoding β-Arrestins: from Structure to function
H. 2020, Casiraghi, M. et al. 2019), double electron-electron resonance (DEER) spectroscopy for high-resolution
- A robust and Efficient FRET-Based Assay for Cannabinoid Receptor Ligands Discovery.
.; Iyer, M. R.; Cinar, R.; Coffey, N. ; Beck, J.; Nettekoven, M.; Benito-Cuesta, I.; Grande, T.; Drawnel, F.; Widmer, G.; Holzer, D.; Van Der V.; Van Der Stelt, M.; Pacher, P.; Gertsch, J.; Ullmer, C.; McCormick, P. J.; Oddi, S.; Spaink, H.
